Genetic testing can predict bladder cancer diagnosis years in advance

Published Date: 17 Mar 2023

Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.

Read Full News

Latest News

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer Sues Johnson & Johnson Over Claim That Prostate Cancer Drug Cuts Risk Of Death

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Todays Updates

Antibiotic Stewardship: Five Tips to Reduce Resistance

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Todays Updates

Antibiotic Stewardship: Five Tips to Reduce Resistance

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Latest News

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

News All Time

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

In infants, laparoscopic robotic pyeloplasty is safe and has a success rate comparable to open surgery.

The results of minimally invasive pyeloplasty (MIP) for the primary cause, ureteropelvic junction obstruction (UPJO), were examined in a recent study.

Recommended News For You

Belzutifan Combo Could be Second-Line Option in Advanced RCC

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

Leukemia cells evade treatment by reshaping their mitochondria, researchers discover

Dense breasts: What it means and what women can do about screening

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

Oral drug combination extends progression-free survival in advanced ER-positive breast cancer

FDA Panel Endorses Capivasertib Use in Prostate Cancer

Recommended Articles For You

Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs 

Understanding the HAS-BLED Score: What It Is and Why It Matters  

Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers 

Understanding Neutrophilia: Causes, Symptoms, and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

2.

Lymph node transfer reduces arm swelling after breast cancer surgery, study shows

3.

Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer

4.

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

5.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

1.

A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

2.

Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies

3.

Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment

4.

Precision Medicine and Genomics: Harnessing Longitudinal Data Modeling to Decode Cancer Progression

5.

Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

3.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

5.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot